Skip to ContentSkip to Navigation
About usNews and EventsNews articles

Major European grant for northern pharmaceutical high-tech companies

01 April 2009

The University of Groningen and the University Medical Center Groningen (UMCG) will be partners in a major research project for the development of new drugs. The project will concentrate on drug delivery and drug targeting. The aim is for drugs to work as efficiently as possible in the body with as few side effects as possible.

The project is coordinated by the Transfer & Liaison Group of the University of Groningen together with Biomade and Business Generator Groningen. The budget is over EUR 7 million, of which nearly EUR 3 million is a European grant. The project has been awarded by the Northern Netherlands Assembly (SNN). The province of Groningen is also supporting the project financially.

Prof. George Robillard, professor of Enzymology and director of the Groningen Life Science business Biomade, is the scientific director of the project. In addition to the University and the UMCG, nine northern SME businesses in the field of marketing innovations are involved.

The underlying aim of the project is to develop the knowledge economy in the North. The project combines knowledge in the field of life sciences with innovation, a biomedical field where the market is expanding.

The participating companies are mainly small-scale high-tech companies. The project offers these innovative enterprises a joint goal towards which they can work together. It is well known that innovative companies grow as a result of cooperation with partners who have something to offer each other.

Drug delivery and drug targeting cover all activities that contribute to as efficient an effect of drugs in the body as possible with as few side effects as possible. More specifically, the aim is to position a drug at exactly the place in the body it is supposed to target.

A drug targeting a malignant tumour, for example, can be treated pharmaceutically in such a way that on administration it only deactivates the blood vessels of the tumour and leaves healthy blood vessels alone. Pharmaceutical and biomedical techniques to mould and form an active drug and stabilize it in such a way that it keeps its shape while passing through the body also fall under the mandate.

Note for the press

More information:
Dr Annemieke Galema, deputy director of the Transfer & Liaison Group, tel. 050-363 5459/5565, e-mail: j.b.e.galema rug.nl

Participating companies: Biomade Technology, BiOrion Technologies, Cellution Biotech, Innocore, Nyken, Synvolux Therapeutics, Triskel Therapeutics, ViciniVax and Vivomicx. The departments of Pharmaceutical Technology and Biopharmacy, Pharmacokinetics and Drug Delivery and Pharmaceutical Biology of the University of Groningen are participating, as well as the departments of Pathology and Medical Biology of the UMCG

Last modified:15 September 2017 3.27 p.m.
printView this page in: Nederlands

More news